Mounjaro®
Starting from £179.99/mo
Start journey Learn moreSemaglutide begins acting in your body from the first dose, but most people notice meaningful appetite changes somewhere between two and eight weeks in. The timeline differs between early biological effects and the kind of weight reduction you can see on the scales. These are prescription-only medicines — whether semaglutide suits you, and which dose is right, is a decision made with a clinician after a proper assessment, not something to judge from the scales alone in week one.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Imagine it's the morning after your first dose. Nothing feels different. That's normal, and it doesn't mean the medicine isn't working.
Semaglutide is a GLP-1 receptor agonist, meaning it activates receptors in the gut and brain involved in appetite signalling and the pace at which your stomach empties. After a subcutaneous injection, the medicine is absorbed gradually through the tissue, peak plasma levels arrive several days later, not within hours. So in week one, the biological machinery is getting going quietly, even if your hunger hasn't shifted yet.
Most people on Wegovy start at 0.25mg, a dose chosen entirely for tolerability rather than effect. The nausea risk is lower at a lower concentration, which is why prescribers don't open at the maintenance dose. Think of it as your system adjusting before the real work begins. A few patients do notice reduced appetite even at this stage; others feel almost nothing different. Both experiences are within the normal range, according to the NHS's patient information on semaglutide.
Side effects, if they appear, tend to cluster in these early weeks, nausea, loose stools, or low-level fatigue. Eating smaller portions and avoiding fatty meals can help. These typically ease as the body adjusts, usually within a couple of weeks of each dose change.
The shift most people describe first isn't dramatic weight loss, it's a change in how hungry they feel. Meals that once felt unsatisfying become enough. The urge to snack between meals fades. Some notice they feel full earlier and find large portions actively unappealing.
This is the GLP-1 mechanism doing its job: slowing gastric emptying and sending satiety signals to the brain. For the majority of people, this appetite dampening becomes noticeable somewhere between weeks two and four, sometimes a little later if the titration schedule means they're still at a lower dose. If you want a fuller picture of how long Wegovy takes to start working, including what to expect at each stage of the titration, our dedicated page walks through the timeline in detail.
Weight change on the scales tends to lag behind the appetite shift by a week or two, simply because a calorie deficit takes time to accumulate into measurable loss. This is worth knowing if you're weighing yourself regularly. Week three with no movement doesn't mean week five won't look different.
There's also a practical timing dimension here. If your first order arrives the week before a holiday, or you start mid-December when routines go sideways, the early weeks may feel harder to read. Consistent weekly injections on the same day (regardless of payday, bank holidays or whatever else is happening) give the most reliable picture of how the medicine is working for you.
Once the dose has stepped up toward the maintenance level (2.4mg for the standard Wegovy injection, prescribed after a graduated titration period), the effects tend to become much more visible. Clinically, the 5% body-weight threshold (often used as a marker of meaningful response) is typically reached in this window for people who respond well.
The STEP 1 trial, published in the New England Journal of Medicine, followed adults with obesity over 68 weeks. Average body weight fell by around 15% at 2.4mg semaglutide alongside lifestyle changes. That kind of result doesn't emerge by month two, it's the product of sustained appetite reduction, dietary adjustment and the full maintenance dose working together over many months. Patients curious about how long semaglutide takes to work across different doses and circumstances will find a detailed breakdown on that page.
NICE's appraisal of semaglutide (TA875) notes that if a person hasn't achieved at least 5% weight loss after six months on the maintenance dose, continuing treatment should be reviewed. That six-month horizon is deliberate: it reflects a realistic assessment window, not an impatient one.
For context on how semaglutide compares to tirzepatide timelines, or how individual results vary, our Wegovy treatment page covers both the evidence and the eligibility picture in more detail.
Starting weight, age, metabolic rate, how closely dietary habits shift alongside treatment, and individual variation in GLP-1 receptor sensitivity all play a role. There is no single correct answer to how long semaglutide takes to work for a given person, even two people on identical doses, starting the same week, can have noticeably different early experiences.
Dose changes matter too. Each step up in the titration schedule tends to bring a renewed appetite effect, and sometimes a brief return of mild nausea. People who have to pause the medicine due to illness, surgery or supply interruptions and then restart may find the timeline resets partially.
If you're weighing up the pace of results or wondering whether a different treatment might suit you better, that's exactly the kind of conversation worth having with a prescriber before or during treatment. Our clinical team reviews every consultation personally, a clinician reads your answers, not a system. The FAQs page also covers some of the most common questions patients raise at the start of treatment.
Cost is sometimes a factor in decisions about how long to continue. Our Wegovy pricing page explains what's included in the cost of private treatment through a regulated UK pharmacy, which is relevant if you're planning for several months of use.
If you'd like to find out whether you're eligible, check your eligibility through a free consultation, it's reviewed the same day by a GPhC-registered prescriber, with no obligation. You can also read Wegovy success stories with before and after accounts from patients who have completed treatment, which gives a realistic sense of the range of outcomes people achieve.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.